Alprazolam — Xanax — is the most prescribed benzodiazepine and also the most problematic. Its clinical character is shaped by one fact: the half-life is approximately 12 hours, the shortest among commonly used BZDs. Everything else about alprazolam's profile flows from that short tail.
- Class
- Short-acting benzodiazepine
- Mechanism
- GABA-A positive allosteric modulator (high potency)
- Typical dose
- 0.25-1 mg three times daily; XR formulation 3-6 mg once daily (start 0.5-1 mg, titrate)
- Half-life
- ~12 hours
- FDA indications
- Panic disorder, anxiety disorders
- Key adverse effects
- Sedation, cognitive impairment, ataxia, anterograde amnesia, rebound anxiety between doses, severe withdrawal (seizures possible), high abuse liability
Black box: Concomitant opioid use; abuse potential and dependence
Among the most prescribed benzodiazepines — and the most problematic. Short half-life produces inter-dose rebound anxiety, leading to escalation. High street value, high diversion potential. Withdrawal among worst of benzodiazepines (severe, prolonged, sometimes seizures). When considering alprazolam, ask: would clonazepam or another longer-acting option serve the same purpose with less risk?
Inter-dose rebound is the first problem. The patient taking alprazolam BID or TID experiences plasma level oscillations — anxiety dampens after each dose, then returns or rebounds as the level drops. The pattern drives dose escalation. Patients commonly move from BID to TID to QID over months. Tolerance develops quickly. The drug "needs itself" to maintain baseline.
Alprazolam is a short-acting, high-potency benzodiazepine whose pharmacokinetics make it both rapidly effective and uniquely difficult to discontinue.
Mechanism note: Alprazolam's short half-life and rapid onset make it effective but uniquely problematic — interdose rebound, hard tapers, and high abuse liability argue for longer-acting alternatives in most chronic use.
Withdrawal is severe — among the worst BZD discontinuation syndromes. Rebound anxiety, tremor, autonomic hyperactivity, insomnia, and in severe cases seizures. Tapering off long-term alprazolam often takes months, not weeks. Many clinicians use clonazepam as a bridge — convert from short-acting alprazolam to long-acting clonazepam, then taper the clonazepam more smoothly.
Abuse liability is the third problem. Alprazolam has rapid onset, substantial euphoric effect at higher doses, high street value, and frequent diversion. It is among the most common BZDs found in overdose deaths, particularly in combination with opioids. PDMP review at every prescription is standard practice.
For the genuine acute panic patient who needs a fast-acting benzodiazepine for PRN use, alprazolam has a role — sparingly. For chronic anxiety, almost any longer-acting alternative serves better with less risk. The question to ask before prescribing alprazolam is: would clonazepam, lorazepam, or a non-BZD option serve the same purpose with less risk? The answer is usually yes.
- Cost
- Generic: ~$10-25/month.
- Generic status
- Generic since 1993. Universally available.
- Formulary typical
- Tier 1 generic.
- Access friction
- Schedule IV — no refills more than 5 within 6 months without new prescription. PDMP review at every prescription. Many practices have policies against initiating in new patients.
Prescriber tip: Rarely a thoughtful new prescription. For established patients on alprazolam, consider clonazepam conversion before tapering. PDMP review mandatory.